0.000USD0.000盤前交易 08/03, 09:30 (美東)
關鍵數據
12.200今開
12.245最高
653.82K成交量
虧損本益比TTM
虧損本益比動
--股利TTM
1.37%換手率
12.080昨收
11.450最低
5.46M成交額
虧損本益比靜
3.84市淨率
0.00%股息率 TTM
-29.90%ROA
12.48052週最高
0.59量比
-73.90M淨利潤
47.77M總股本
-0.7757每股盈餘TTM
0.10Beta
-30.92%ROE
1.16052週最低
6.58%振幅
--毛利率
681.43M總市值
-1.51回報/風險
5.96%風險率
Climb Bio Inc新聞
即將為您帶來更多新聞,敬請期待。 。 。
收益預測
Ionis Pharmaceuticals Inc
IONS
27
Kymera Therapeutics Inc
KYMR
24
技術指標
財務指標
每股收益

由於公司未披露,未能獲取相關數據
營業總收入

由於公司未披露,未能獲取相關數據
Climb Bio Inc簡介
Climb Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in a Phase Ib/IIa clinical trial. The Company is also developing CLYM116, an anti-APRIL antibody, in investigational new drug applications (IND)-enabling studies for IgA nephropathy (IgAN).
公司代碼CLYM
公司Climb Bio Inc
CEOBrennan (Aoife M)
網址https://climbbio.com/
公司股東
常見問題
Climb Bio Inc(CLYM)的當前股價是多少?
Climb Bio Inc(CLYM)的當前股價是 11.90。
Climb Bio Inc股票的52週最高點是多少?
Climb Bio Inc股票的52週最高點是12.48。
Climb Bio Inc股票的52週最低點是多少?
Climb Bio Inc股票的52週最低點是1.16。
Climb Bio Inc的市值是681.43M。
現在Climb Bio Inc(CLYM)的股票是買入、持有還是賣出?
根據分析師評級,Climb Bio Inc(CLYM)的總體評級為STRONG BUY,目標價格為21.14。
Climb Bio Inc(CLYM)股票的每股收益(EPS TTM)是多少
Climb Bio Inc(CLYM)股票的每股收益(EPS TTM)是-0.88。